Table 6.

Current and recent perioperative gene and vaccine therapy trials for MIBC*

Institution	Therapy	Trial description	Status/Outcomes	Trial ID
Uppsala University	Gene	Phase 1/IIa Intravesical instillation of AdCD40L that may improve anti-tumor immune response. Cystectomy followed phase 1 trial.	Completed. 8 patients with limited complications. Successful gene transfer detected in biopsies [33].	NCT00891748
Celldex Therapeutics	Vaccine	Phase II neoadjuvant and adjuvant administration of CDX-1307 vaccine with chemotherapy for bladder tumors expressing B-HCG protein for patients undergoing radical cystectomy.	Terminated due to lack of enrollment.	NCT01094496
MSKCC and NCI	Vaccine	Phase 1 adjuvant administration of NY-ESO-1 peptide vaccine with BCG + sargramostim for tumors expressing NY-ESO-1 or LAGE-1 antigens. Patients previously underwent radical cystectomy.	Competed. Results unreported.	NCT00070070

*Table does not include trials for multiple solid tumors that may include bladder cancer as a subset.

MSKCC = Memorial Sloan-Kettering Cancer Center.

NCI = National Cancer Institute.